The main active ingredient of this product is Ammonium Bromhexine Hydrochloride.

Chemical Name: trans-4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride.

Structural Formula:

Molecular Formula: C13H18Br2N2O·HCl

Molecular Weight: 414.57

Description:

The product is a white or off-white tablet.

Indications:

It is suitable for the treatment of acute and chronic respiratory diseases with abnormal mucus secretion and impaired sputum clearance, such as acute exacerbation of chronic bronchitis, wheezing bronchitis, bronchiectasis, and bronchial asthma.

Specifications: 30mg

Dosage and Administration:

Adults: Take 1 tablet three times a day. If taken twice a day, the dosage can be increased to 2 tablets per dose to improve efficacy.

Children: The recommended dosage is 1.2-1.6mg per kilogram of body weight per day.

Take the medication after meals with liquid.

Adverse Reactions:

The product is generally well-tolerated.

Allergic reactions are rare and mainly manifest as rashes. Severe acute allergic reactions have been reported in very few cases, but their relationship with Ammonium Bromhexine Hydrochloride cannot be confirmed, as these patients usually exhibit allergies to other substances as well.

Contraindications:

It should not be used in patients known to be allergic to Ammonium Bromhexine Hydrochloride or other ingredients of the formulation.

Precautions:

Not yet specified.

Use in Pregnant and Nursing Women:

Preclinical trials and extensive clinical experience during the third trimester of pregnancy have shown no adverse effects. However, caution should be exercised, especially during the first three months of pregnancy. The drug can enter breast milk but should have no effect on the infant at therapeutic doses.

Use in Children:

Not yet specified.

Use in the Elderly:

Not yet specified.

Drug Interactions:

Simultaneous use with antibiotics (such as amoxicillin, cefuroxime, erythromycin, and tetracycline) can increase the concentration of antibiotics in lung tissue. No clinically relevant adverse effects have been reported with concomitant use of other drugs.

Overdosage:

No reports of overdose symptoms have been documented. If it occurs, symptomatic treatment should be administered.

Pharmacology and Toxicology:

The product is a mucolytic agent that can increase the secretion of respiratory mucous gland, reduce mucus gland secretion, and thereby reduce mucus viscosity. It can also promote the secretion of pulmonary surfactants, increase bronchial ciliary movement, and facilitate expectoration of sputum.

Pharmacokinetics:

Ammonium Bromhexine Hydrochloride is rapidly and almost completely absorbed after oral administration, with a peak plasma concentration reached between 0.5 and 3 hours. The plasma protein binding rate within the therapeutic range is approximately 90%. It distributes rapidly and significantly from the blood to the tissues, with the lungs being the primary target organ. The plasma half-life is approximately 7-12 hours, and no accumulation effect has been observed. Ammonium Bromhexine Hydrochloride is mainly metabolized in the liver in a conjugated form, and approximately 90% is excreted by the kidneys.

Storage:

Store in a tightly closed container, protected from light, at a temperature between 10°C and 30°C.

Packaging:

Aluminum-plastic packaging.

Options: 8 tablets, 10 tablets, 12 tablets, 14 tablets, 16 tablets, 20 tablets, 30 tablets, or according to customer requirements.

Manufacturer:

Not yet specified.

Approval Number:

Not yet specified.

Date of Preparation:

Not yet specified.

Note: The information provided here is based on the Chinese product label. Please consult the relevant product documentation and medical professionals for accurate and up-to-date information.